Durability of antibody response against hepatitis B virus in healthcare workers vaccinated as adults
Auteur Naveen Gara
Auteur Adil Abdalla
Auteur Elenita Rivera
Auteur Xiongce Zhao
Auteur Jens M. Werner
Auteur T. Jake Liang
Auteur Jay H. Hoofnagle
Auteur Barbara Rehermann
Auteur Marc G. Ghany
Volume 60
Numéro 4
Pages 505-513
Publication Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
ISSN 1537-6591
Date Feb 15, 2015
Résumé BACKGROUND: Follow-up studies of recipients of hepatitis B vaccine from endemic areas have reported loss of antibody to hepatitis B surface antigen (anti-HBs) in a high proportion of persons vaccinated at birth. In contrast, the long-term durability of antibody in persons vaccinated as adults in nonendemic areas is not well defined. We aimed to assess the durability of anti-HBs among healthcare workers (HCWs) vaccinated as adults and response to a booster among those without protective levels of antibody. METHODS: Adult HCWs aged 18-60 at the time of initial vaccination were recruited. All were tested for hepatitis B surface antigen (HBsAg), antibody to hepatitis B core antigen (anti-HBc), and anti-HBs level. HCWs with anti-HBs <12 mIU/mL were offered a booster and levels were measured 1, 7, and 21 days afterward. RESULTS: Anti-HBs levels were <12 mIU/mL in 9 of 50 (18%), 13 of 50 (26%), and 14 of 59 (24%) HCWs 10-15, 16-20, and >20 years postvaccination, respectively, (P = ns). Four HCWs were anti-HBc positive; none had HBsAg. By logistic regression, older age at vaccination was the only predictor of inadequate anti-HBs level (P = .0005). Thirty-four of 36 subjects with inadequate anti-HBs levels received a booster and 32 (94%) developed levels >12 mIU/mL within 3 weeks. CONCLUSIONS: Anti-HBs levels decrease after 10-31 years and fall below a level considered protective in approximately 25% of cases. The rapid and robust response to a booster vaccine suggests a long-lasting amnestic response. Hepatitis B vaccination provides long-term protection against hepatitis B and booster vaccination does not appear to be necessary in HCWs. Clinical Trials Registration. NCT01182311.
Chercher cette référence sur : Google Scholar, Worldcat
doi:10.1093/cid/ciu867
Laisser une réponse
Vous devez etre connectez Pour poster un commentaire